| Name | Title | Contact Details |
|---|
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
We Develop first in class therapies for basal cell carcinomas, including those in gorlin syndrome.
Gen Trak (Main) is a Liberty, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Chi Scientific is a Maynard, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Culture Biosciences develops automated bioreactor infrastructures and runs it as a service for biotech companies.